- Share
- [](https://www.facebook.com/sharer.php?u=https://about.ebsco.com/markdownify/node/82916)
- [](<http://twitter.com/intent/tweet?text=EBM Focus: The Subtle Sufficiency of “Insufficient” Recommendations&url=https://about.ebsco.com/markdownify/node/82916&via=EBSCO>)
- [](<http://www.linkedin.com/shareArticle?mini=true&url=https://about.ebsco.com/markdownify/node/82916&title=EBM Focus: The Subtle Sufficiency of “Insufficient” Recommendations&summary=The United States Preventative Services Task Force (USPSTF) issued an “I” clinical practice recommendation for type 2 diabetes screening in children. This EBM Focus article dissects what that means.&source=Health-Notes>)
- [](<mailto:?subject=Thought you might want to read this...&body=EBM Focus: The Subtle Sufficiency of “Insufficient” Recommendations%0D%0Ahttps://about.ebsco.com/markdownify/node/82916>)
 


  # EBM Focus: The Subtle Sufficiency of “Insufficient” Recommendations

 

 

    The United States Preventative Services Task Force (USPSTF) issued an “I” clinical practice recommendation for type 2 diabetes screening in children. This EBM Focus article dissects what that means. 

 ![child physician high five doctors appointment blog image    ](/sites/default/files/acquiadam-assets/child-physician-high-five-doctors-appointment-blog-image-780.jpg) 

 

[Katharine DeGeorge, MD, MS](/health-notes/bio/katharine-degeorge-md-ms)

 

 10 November 2022 

 

 

The United States Preventive Services Task Force (USPSTF) recently updated its clinical practice recommendation regarding [screening for type 2 diabetes](https://pubmed.ncbi.nlm.nih.gov/36098719/) in children and adolescents, coming up with an “I” statement of insufficient evidence due to lack of studies demonstrating that interventions for screen-detected type 2 diabetes improve health outcomes.

The American Diabetes Association (ADA) also updated their [clinical guidance in 2022](https://ada.silverchair-cdn.com/ada/content_public/journal/care/issue/45/supplement_1/10/standards-of-care-2022-copyright-stamped-updated-01062022.pdf?Expires=1668433078&Signature=02f8Ti3UeD-F~hhvu3Dg-5VHhl3Hu6xWPMzqFyZeDEflY~9YEMnAD0kYnfoDP4~jQlz3ei17-KDOzujCU3wez7flRI2uQQdHOQetfq6O~nozAaT-K2ti10IN5oZgcoTjLABmX3s~fSANN6Rk7pxCyBNM2tcY3KMMbkWuUCbw6HPs-AuyoPYkDO2oJ0KftxaGoLPpjiX3lYJkjuuGhXUpyWGb4Yftre~TToiSrWcCeaqbyH1HMnq4p-HagDRawimYaSGYOjJeN9Pkjk~Svrg1KkIaT0Im2VSLlujz4zcJvLnid7f0A0pEG2PmVaItf0zMpLAXalN5Fo36cSa~jDOy2w__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA), but this group offers up a Grade A/B recommendation that we should consider screening in children who are at least 10 years old or pubertal and who have risk factors.

This happens all the time — differing clinical practice recommendations from different professional organizations. Which recommendation should we follow? Who do we believe? And why?

First, we need to clarify the scope of the recommendations. In this case, the USPSTF is concluding on the general population of all children and adolescents, whereas the ADA is suggesting screening in a subpopulation who are overweight and have other risk factors. So, it’s a little like comparing apples to apple slices.

It is also important to consider sources of potential bias, which can be intellectual, financial, or philosophical. The USPSTF is an independent, government-funded panel of volunteer, nationally recognized experts in prevention and evidence-based medicine. These experts have no significant conflicts of interest and engage in a process of systematic appraisal of data in a transparent and reproducible way. The ADA is a private advocacy group funded in part by the pharmaceutical industry, so there is potential for a financial incentive when more patients are diagnosed with and treated for diabetes.

Philosophical differences among professional organizations tend to look like a bias towards *action* or *inaction* when data is lacking. In general, specialty organizations tend to err on the side of “doing something” whereas primary care groups tend to “first do no harm” when there is not enough evidence to draw a firm conclusion.

Screening to identify disease earlier than it would manifest naturally is not always beneficial. Some diseases never go on to cause clinically important harms, and some will spontaneously improve. [Prostate cancer](https://www.dynamedex.com/prevention/prostate-cancer-screening) is a good example of when simply identifying a disease may have more harms than benefits. When it comes to type 2 diabetes, we still don’t know whether identifying children by screening leads to better long-term clinical outcomes. But we do know that overdiagnosis can lead to overtreatment which can result in harm.

An “I” statement of insufficient evidence from the USPSTF can be mistaken as a weaker recommendation or an “I don’t know” statement. It’s not, though. An “I” statement offers transparency in appraisal of the evidence, or lack thereof, and often stands as more valid and trustworthy than recommendations that use stronger language but are based on lower quality evidence or expert opinion.

**Practice Point: Interventions for screen-detected type 2 diabetes in children and adolescents have not \[yet?\] been shown to improve health outcomes. Current evidence is insufficient to recommend screening.**

**EBM Pearl: An “I” statement from the USPSTF does not stand for “I don’t know.” Take the time to critically consider more strongly worded recommendations from other groups when the USPSTF concludes that the evidence is insufficient.**

For more information, see the topic [**Diabetes Mellitus Type 2 Screening**](https://nam10.safelinks.protection.outlook.com/?url=https%3A%2F%2Fgo.ebsco.com%2FNjg5LUxOUS04NTUAAAGG_v_6qxSLrrDftKg-DCNvzqPZt8R1O9Zb-4ovQvorWt1IYfnkXdfJyA8mnL774XYPZGzEA5c%3D&data=05%7C01%7Chmarshall%40ebsco.com%7Cd48d55bfd00a41f59b2308da9bcd2120%7C50fa36ca7dd344f19e3f1bf39a3963a5%7C0%7C0%7C637993602584963957%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=8oCX3KMyc7AU0X6JBA5A3wRQnf3HQozf9AmClw3WhWk%3D&reserved=0) in DynaMed.



 



  [ Sign up for EBM Focus ](https://more.ebsco.com/EBM-Focus-Newsletter-Signup.html) 

 



 

 



 

 Category: [Clinical Practice Perspectives

 ](/blogs/health-notes/category/clinical-practice-perspectives) 

 Tags:  [Evidence–based medicine](/blogs/health-notes/tag/evidence–based-medicine)  [EBMFocus](/blogs/health-notes/tag/ebmfocus) 

 

 

 

- Share
- [](https://www.facebook.com/sharer.php?u=https://about.ebsco.com/markdownify/node/82916)
- [](<http://twitter.com/intent/tweet?text=EBM Focus: The Subtle Sufficiency of “Insufficient” Recommendations&url=https://about.ebsco.com/markdownify/node/82916&via=EBSCO>)
- [](<http://www.linkedin.com/shareArticle?mini=true&url=https://about.ebsco.com/markdownify/node/82916&title=EBM Focus: The Subtle Sufficiency of “Insufficient” Recommendations&summary=The United States Preventative Services Task Force (USPSTF) issued an “I” clinical practice recommendation for type 2 diabetes screening in children. This EBM Focus article dissects what that means.&source=Health-Notes>)
- [](<mailto:?subject=Thought you might want to read this...&body=EBM Focus: The Subtle Sufficiency of “Insufficient” Recommendations%0D%0Ahttps://about.ebsco.com/markdownify/node/82916>)
 
 

 

 

 

  ## Related Posts

[ ![patient smiling blog image template    ](/sites/default/files/acquiadam-assets/patient-smiling-blog-image-template-780.jpg) 

 ](/blogs/health-notes/ebm-focus-two-steps-best-screening-test-gestational-diabetes)

[EBM Focus: Two Steps to the “Best” Screening Test for Gestational Diabetes](/blogs/health-notes/ebm-focus-two-steps-best-screening-test-gestational-diabetes)

 8 April 2021 

 

 

 

 

 



[ ![expert opinion low quality evidence blog image    ](/sites/default/files/acquiadam-assets/expert-opinion-low-quality-evidence-blog-image-780.jpg) 

 ](/blogs/health-notes/ebm-focus-expert-opinion-and-low-quality-evidence-still-drive-strong)

[EBM Focus: Expert Opinion and Low-quality Evidence Still Drive Strong Recommendations in Cardiology](/blogs/health-notes/ebm-focus-expert-opinion-and-low-quality-evidence-still-drive-strong)

 10 June 2019 

 

 

 

 

 



[ ![allied health meeting blog image template    ](/sites/default/files/acquiadam-assets/allied-health-meeting-blog-image-template-780.jpg) 

 ](/blogs/health-notes/ebm-focus-new-colorectal-cancer-screening-recommendations-developed-population)

[EBM Focus: New Colorectal Cancer Screening Recommendations - Developed for a Population But Applied to Individuals ](/blogs/health-notes/ebm-focus-new-colorectal-cancer-screening-recommendations-developed-population)

 20 July 2021